2. Academic Validation
  3. Seco-4-methyl-DCK derivatives as potent chemosensitizers

Seco-4-methyl-DCK derivatives as potent chemosensitizers

  • Bioorg Med Chem Lett. 2019 Jan 1;29(1):28-31. doi: 10.1016/j.bmcl.2018.11.023.
Yalan Guo 1,  Ke Wang 1,  Xiaoyu Chen 2,  Haihong Li 1,  Qi Wan 1,  Susan Morris-Natschke 3,  Kuo-Hsiung Lee 4,  Ying Chen 5
Affiliations

Affiliations

  • 1 Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China.
  • 2 Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China; Department of Materials Science & Engineering, Faculty of Engineering, Monash University, Clayton, VIC 3800, Australia.
  • 3 Natural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599-7568, USA.
  • 4 Natural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599-7568, USA; Chinese Medicine Research and Development Center, China Medical University and Hospital, Taichung, Taiwan. Electronic address: khlee@unc.edu.
  • 5 Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China. Electronic address: yingchen71@fudan.edu.cn.
PMID: 30455148 DOI: 10.1016/j.bmcl.2018.11.023
Abstract

Twenty-five seco-4-methyl-DCK derivatives were designed, synthesized and evaluated for chemoreversal activity when combined with paclitaxel or vincristine in two drug-resistant Cancer cell lines (A2780/T and KB-V) respectively. Most of the new compounds displayed moderate to significant MDR reversal activities in the P-gp overexpressing A2780/T and KB-V cells. Especially, compounds 7o and 7y showed the most potent chemosensitization activities with more than 496 and 735 reversal ratios at a concentration of 10 μM. Unexpectedly the newly synthesized compounds did not show chemosensitization activities observed in a non-P-gp overexpressing cisplatin resistant human ovarian Cancer cell line (A2780/CDDP), implying that the MDR reversal effects might be associated with P-gp overexpression. Moreover, these compounds did not exhibit significant antiproliferative activities against nontumorigenic cell lines (HUVEC, HOSEC and T29) compared to the positive control verapamil at the tested concentration, which suggested better safety than verapamil. The pharmacological actions of the compounds will be studied further to explore their merit for development as novel candidates to overcome P-gp mediated MDR Cancer.

Keywords

Chemosensitizer; MDR reversal activity; P-gp; Seco-4-methyl-DCK.

Figures